Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 291 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 291 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $12,451.89. Following the completion of the transaction, the president now directly owns 1,443,567 shares in the company, valued at $61,770,231.93. The trade was a 0.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, September 3rd, Stephen Hoge sold 318 shares of Moderna stock. The shares were sold at an average price of $76.99, for a total transaction of $24,482.82.

Moderna Trading Up 2.8 %

Shares of MRNA opened at $44.26 on Tuesday. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The firm has a market capitalization of $17.03 billion, a P/E ratio of -7.60 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $51.98 and its 200 day simple moving average is $90.21.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.39) EPS. On average, equities research analysts forecast that Moderna, Inc. will post -9.44 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research reports. Leerink Partners lowered their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Berenberg Bank began coverage on shares of Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price objective for the company. UBS Group lowered their target price on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. Finally, HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research note on Monday, November 18th. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $83.33.

Institutional Investors Weigh In On Moderna

Several institutional investors have recently bought and sold shares of the business. State Street Corp lifted its holdings in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Moderna in the third quarter valued at about $23,825,000. International Assets Investment Management LLC raised its holdings in shares of Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after buying an additional 316,552 shares during the period. Finally, State of Michigan Retirement System lifted its position in Moderna by 201.9% during the 2nd quarter. State of Michigan Retirement System now owns 274,248 shares of the company’s stock worth $32,567,000 after acquiring an additional 183,407 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.